CD44 and breast carcinoma: The data used in this case study for evaluation and validation comes primarily from a study that profiled and compared normal breast epithelium tissue obtained from reduction mammoplasties and highly tumorigenic breast cancer cells isolated from tumors (ESA+ CD44+ CD24-/low Lin-) [35].